Abstract
The vascular pattern of amyloid beta (Aβ) deposition in the brain is commonly referred to as cerebral amyloid angiopathy (CAA) (1). CAA is an important cause of cerebral hemorrhages and may lead to ischemic infarction and dementia (2). A pure form of CAA, without parenchymal lesions, has been documented in hereditary cerebral hemorrhage, Dutch type, sporadic idiopathic CAA and in cerebrovascular malformations (3–5). Cerebrovascular amyloid deposition is associated with aging, and CAA is an important feature of several disorders associated with mutations in the amyloid precursor protein (APP) gene, as well as in Down’s syndrome and Alzheimer’s disease (AD) (6–8). Indeed, CAA is a key pathologic finding in 80–90% of AD cases (9,10). A recent study of 201 autopsy cases of elderly Japanese shows that the incidence and severity of CAA are significantly higher in AD cases compared to non-AD cases (11). Also, some genetic risk factors associated with the AD are involved in the pathogenesis of CAA, including apolipoprotein E (apoE) genotype, presenilin 1, and apantichymotrypsin (12–14).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Matsubara E, Shoji M, Abe K, Frangione B, Ghiso J. Vascular amyloidosis in neurodegenerative conditions. Drug News Perspect 2002;15:439–44.
Ghiso J, Frangione B. Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia. J Alzheimer Dis 2001;3:65–73.
Levy E, Carman MD, Fernandez-Madrid IJ, et al. Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990;248:1124–1126.
Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987;18:311–324.
Ghiso J, Wisniewski T, Frangione B. Unifying features of systemic and cerebral amyloidosis. Mol Neurobiol 1994;8:49–64.
Donahue JE, Khurana JS, Adelman LS. Intracerebral hemorrhage in two patients with Down’s syndrome and cerebral amyloid angiopathy. Acta Neuropathol 1998;95:213–216.
Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002;109:813–836.
Revesz T, Holton JL, Lashley T, et al. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol 2002;12:343–357.
Mandybur TI. The incidence of cerebral amyloid angiopathy in Alzheimer’s disease. Neurology 1975;25:120–126.
Ellis RJ, Olichney JM, Thai LJ, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: The CERAD experience, part XV. Neurology 1996;46:1592–1596.
Yamada M. Risk factors for cerebral amyloid angiopathy in the elderly. Ann N Y Acad Sci 2002;977:37–44.
Premkumar DRD, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E ɛ4 in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer’s disease. Am J Pathol 1996;148:2083–2095.
Yamada M, Sodeyama N, Itoh Y, et al. Association of presenilin-1 polymorphism with cerebral amyloid angiopathy in elderly. Stroke 1997;28:2219–2221.
Yamada M, Sodeyama N, Itoh Y, et al. Association of alpha 1-antichymotrypsin polymorphism with cerebral amyloid angiopathy. Ann Neurol 1998;44:129–131.
Chalmers K, Wilcock GK, Love S. APOE var epsilon 4 influences the pathological phenotype of Alzheimer’s disease by favouring cerebrovascular over parenchymal accumulation of Abeta protein. Neuropathol Appl Neurobiol 2003;29:231–238.
Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of A (3 to physiologically relevant proteolytic degradation. Lancet 2003;361:1957–1958.
Yamada M, Sodeyama N, Itoh Y, et al. Association of neprilysin polymorphism with cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 2003;74:749–751.
Natte R, de Boer WI, Maat-Schieman ML, et al. Amyloid beta precursor protein-mRNA is expressed throughout cerebral vessel walls. Brain Res 1999;828:179–183.
Akiyama H, Ikeda K, Kondo H, McGeer PL. Thrombin accumulation in brains of patients with Alzheimer’s disease. NeurosciLett 1992;146:152–154.
McGeer PL, Klegeris A, Walker DG, Yasuhara O, McGeer EG. Pathological proteins in senile plaques. Tohoku J Exp Med 1994;174:269–277.
Ciallella JR, Figueiredo H, Smith-Swintosky V, McGillis JP. Thrombin induces surface and intracellular secretion of amyloid precursor protein from human endothelial cells. Thromb Haemost 1999;81:630–637.
Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Brain Res Mol Brain Res 1992;16:128–134.
Grammas P, Ovase R. Inflammatory factors are elevated in brain microvessels in Alzheimer’s disease. Neurobiol Aging 2001;22:837–842.
Zlokovic BV, Martel CL, Matsubara E, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci 1996;93:4229–234.
Mackic JB, Stins M, McComb JG, et al. Human blood-brain barrier receptors for Alzheimer’ amyloid-β. J Clin Invest 1998;102:734–743.
Grammas P, Yamada M, Zlokovic B. The cerebromicrovascular: a key player in the pathogenesis of Alzheimer’s disease. J Alzheimer Dis 2002;4:217–223.
Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, Frangione B. Blood-brain barrier transport of circulating Alzheimer’s amyloid beta. Biochem Biophys Res Commun 1993;197:1034–1040.
Martel CL, Mackic JB, Matsubara E, et al. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer’s amyloid beta. J Neurochem 1997;69:1995–2004.
Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907–913.
Yan SD, Stern D, Kane MD, Kuo YM, Lampert HC, Roher AE. RAGE-Ab interactions in the pathophysiology of Alzheimer’s disease. RestorNeurol Neurosci 1998;12:167–173.
Mackic JB, Weiss MH, Miao W, et al. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer’s amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J Neurochem 1998;70:210–215.
Mackic JB, Bading J, Ghiso J, et al. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer’s disease lesions. Vascul Pharmacol 2002;38:303–313.
Maness LM, Banks WA, Podlisny MB, Selkoe DJ, Kastin AJ. Passage of human amyloid beta-protein 1–40 across the murine blood-brain barrier. Life Sci 1994;55:1643–1650.
Poduslo JF, Curran GL, Haggard JJ, Biere AL, Selkoe DJ. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid beta-protein 1–40 at the blood-brain barrier. Neurobiol Res 1997;4:27–34.
Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 2003;29:106–117.
Weller RO, Yow HY, Preston SD, Mazanti I, Nicoll JA. Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer’s disease. Ann NY Acad Sci 2002;977:162–168.
Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer’s amyloid-ss(l–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489–1499.
Bading JR, Yamada S, Mackic JB, et al. Brain clearance of Alzheimer’s amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target 2002;10:359–368.
Grammas P, Roher A, Ball MJ. Increased accumulation of cAMP in cerebral microvessels in Alzheimer’s disease. Neurobiol Aging 1994;15:113–116.
Cashman RE, Grammas P. cAMP-dependent protein kinase in cerebral microvessels in aging and Alzheimer’s disease. Mol Chem Neuropathol 1995;26:247–258.
Grammas P, Moore P, Botchlet T, et al. Cerebral microvessels in Alzheimer’s have reduced protein kinase C activity. Neurobiol Aging 1995;16:563–569.
Moore P, White J, Christiansen V, Grammas P. Protein kinase C-ζ activity but not level is decreased in Alzheimer’s disease microvessels. Neurosci Lett 1998;254:29–32.
Pakaski M, Balaspiri L, Checler F, Kasa P. Human amyloid-beta causes changes in the level of endothelial protein kinase C and to alpha isoform in vitro. Neurochem Int 2003;41:409–414.
Suhara T, Magrane J, Rosen K, et al. Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol Aging 2003;24:437–51.
Dorheim MA, Tracey WR, Pollock JS, Grammas P. Nitric oxide is elevated in Alzheimer’s brain microvessels. Biochem Biophy Res Commun 1994;205:659–665.
Venturini G, Colasanti Persichini T, Fioravanti E, Ascenzi P, Palomba L, Cantoni O. Musci G. Beta amyloid inhibits NOS activity by subtracting NADPH availability. FASEB J 2002;16:1970–1972.
Grammas P, Botchlet T, Fugate R, Ball MJ, Roher AE. Alzheimer disease amyloid proteins inhibit brain endothelial cell proliferation in vitro. Dementia 1995;6:126–130.
Giri R, Shen Y, Stins M, et al. Beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol 2000;279:1772–1781.
Giri R, Selvaraj S, Miller CA, et al. Effect of endothelial cell polarity on beta-amyloid-reduced migration of monocytes across normal and AD endothelium. Am J Physiol 2002;283:C895–C904.
Blanc EM, Toborek M, Mark RJ, Hennig B, Mattson MP. Amyloid beta-peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces apoptosis in vascular endothelial cells. J Neurochem 1997;68:1870–1881.
Hase M, Araki S, Hayashi H. Fragments of amyloid beta induce apoptosis in vascular endothelial cells. Endothelium 1997;5:221–229.
Xu J, Chen S, Ka G, et al. Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J Cereb Blood Flow Metab 2001;21:702–710.
Munoz FJ, Opazo C, Gil-Gomez G, et al. Vitamin E but not 17beta-estradiol protects against vascular toxicity induced by beta-amyloid wild type and the Dutch amyloid variant. J Neurosci 2002;22:3081–3089.
Yin KJ, Lee JM, Chen SD, Xu J, Hsu CY. Amyloid-beta induces Smac release via AP—1/Bim activation in cerebral endothelial cells. J Neurosci 2002;22:9764–9770.
Christie R, Yamada M, Moskowitz M, Hyman B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol 2001;158:1065–1071.
Davis J, Wagner MR, Zhang W, Xu F, Van Nostrand WE. Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J Biol Chem 2003;278:19,054–19,061.
Jung SS, Zhang W, Van Nostrand WE. Pathogenic Abeta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J Neurochem 2003;85:1208–1215.
Neuroinflammation Working Group. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000;21:383–l21.
McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 1996;47:425–432.
Hull M, Fiebich BL, Schumann G, Lieb K, Bauer J. Anti-inflammatory substances-a new therapeutic option in Alzheimer’s disease. Drug Discovery Today 1999;4:275–282.
Halliday GM, Shepard CE, McCann H, et al. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer’s disease. Arch Neurol 2000;57:831–836.
Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 2000;20:5709–5714.
Gupta A, Pansari K. Inflammation and Alzheimer’s disease. Int J Clin Pract 2003;57:36–39.
Launer L. Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer’s disease: dissecting the epidemiological evidence. Drugs 2003;63:731–739.
Frohman EM, Frohman TC, Gupta S, de Fourgerolles A, Van Den Noort S. Expression of intercellular adhesion molecule (ICAM-1) in Alzheimer’s disease. J Neurol Sci 1991;106:105–111.
Pereira HA, Kumar P, Grammas P. Expression of CAP37, a novel inflammatory mediator in Alzheimer’s disease. Neurobiol Aging 1996;17:753–759.
Grammas P, Ovase R. Cerebrovascular transforming growth factor-p contributes to inflammation in the Alzheimer’s disease brain. Am J Pathol 2002;160:1583–1587.
Suo Z, Tan J, Placzek A, Crawford F, Fang C, Mullan M. Alzheimer: β-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines, and CD40. Brain Res 1998;807:110–117.
Townsend KP, Obregon D, Quadros A, et al. Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Ann NY Acad Sci 2002;977:65–76.
Paris D, Townsend KP, Humphrey J, Obregon DF, Yokota K, Mullan M. Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aorta. Atherosclerosis 2002;161:293–299.
Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer’s disease. J Neuroimmunol 2003;173:32–41.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Grammas, P. (2005). Amyloid Beta and the Cerebral Vasculature. In: Paul, R.H., Cohen, R., Ott, B.R., Salloway, S. (eds) Vascular Dementia. Current Clinical Neurology. Humana Press. https://doi.org/10.1385/1-59259-824-2:267
Download citation
DOI: https://doi.org/10.1385/1-59259-824-2:267
Publisher Name: Humana Press
Print ISBN: 978-1-58829-366-4
Online ISBN: 978-1-59259-824-3
eBook Packages: MedicineMedicine (R0)